The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
University of Alabama at Birmingham
Birmingham, Alabama, United States
Orlando Clinical Research Center
Orlando, Florida, United States
IU Center for Clinical STD Research
Indianapolis, Indiana, United States
UNC Clinical Research - Raleigh
Raleigh, North Carolina, United States
Group 1. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients with a history of clinical genital herpes lesions
Group 2. Reduction of HSV DNA PCR positive days in HSV-2 seropositive patients without a history of clinical genital herpes lesions
reduction of HSV DNA PCR positive days without lesions in HSV-2 seropositive patients with and without a history of clinical genital herpes lesions
quantitative HSV DNA PCR, during the days with positive HSV-2 shedding.
time to the first recurrence of genital herpes and number of genital herpes recurrence episodes
oral HSV-1 and/or HSV-2 shedding in HSV-1 and HSV-2 seropositive patients
reduction of HSV DNA PCR positive days with lesions in HSV-2 seropositive patients with and without a history of clinical genital herpes lesions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lynne Health Science Institute
Oklahoma City, Oklahoma, United States
Westover Heights Clinic
Portland, Oregon, United States
University of Washington - Virology Research Clinic
Seattle, Washington, United States